No­vo Nordisk se­cures FDA ap­proval of RNAi ther­a­py from $3.3B Dicer­na takeover

Two years lat­er, No­vo Nordisk’s $3.3 bil­lion buy­out of Dicer­na Phar­ma­ceu­ti­cals’ RNAi plat­form is be­gin­ning to pay off.

No­vo scored an ap­proval on Mon­day for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER